DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
NOVATO, Calif., May 10, 2017 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 16, 2017 at 3:00 pm PT in Las Vegas, NV.
The live and archived webcast of the company presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.
About Ultragenyx
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc. Investors & Media Ryan Martins 844-758-7273
